Alphabet Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -45

ARK Invest Exits $28M Alphabet (GOOGL) Position, Piles Into Meta (META) Stock

AI-generated analysis

πŸ“‰ ARK Invest sold 84,392 shares of Alphabet (GOOG) valued at $28.6 million on September 9, 2026, causing the stock to decline 2.28%.

πŸ”„ This transaction represents a continuation of ARK's established pattern of systematically decreasing its Alphabet allocation rather than an isolated event.

πŸ’‘ Mizuho Securities analyst Lloyd Walmsley noted that Meta's new AI agent may reignite investor concerns about Google's Gemini technology and search revenue disruption.

πŸ“ˆ ARK simultaneously purchased 43,091 shares of Meta Platforms worth $26.4 million following the company's Muse AI agent unveiling.

🧬 The firm expanded its biotechnology positions by acquiring stakes in Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics.

πŸ“‰ ARK reduced its Tempus AI holdings by approximately $1.5 million as part of its broader portfolio rebalancing strategy.

Risk Factors
  • ARK Invest divested $28.6 million in Alphabet shares, signaling a loss of confidence or strategic reallocation away from the company.
  • The sale coincided with a 2.28% stock decline, reflecting immediate negative market reaction to the institutional exit.
  • Analysts suggest Meta's new AI agent poses a competitive threat to Google's Gemini technology and could disrupt search engine revenues.
Full Analysis
ARK Invest executed significant portfolio adjustments on September 9, 2026, offloading 84,392 shares of Alphabet (GOOG) valued at approximately $28.6 million through its ARKK and ARKW funds. This divestiture resulted in a 2.28% decline for Alphabet stock during the trading session, marking a continuation of the firm's systematic reduction in its allocation to the company across multiple recent sessions. The strategic shift was driven by Meta Platforms' unveiling of its Muse AI agent, which caused Meta shares to surge 6.55%. Mizuho Securities analyst Lloyd Walmsley suggested that this development reignited investor apprehension regarding Google's Gemini AI technology and potential disruption to conventional search engine revenues from AI-powered agents, providing context for the capital reallocation away from Alphabet. ARK Invest simultaneously increased its holdings in Meta Platforms by acquiring 43,091 shares worth $26.4 million and expanded positions in several biotechnology firms including Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics. The firm also reduced its Tempus AI holdings by approximately $1.5 million, demonstrating a clear strategic pivot toward Meta and specific biotech equities while reducing exposure to Alphabet.